Work

Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

Year: 2019

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz244.020

Authors: W. Wick, G. Tabatabai, M. Schuler, K. Rorhberg, S.P. Chawla, F. Janku, D. Schiff, V. Heinemann, Y. Narita, Y. Ando, H.J. Lenz, M. Ikeda, I. Genvresse, C. Rentzsch, S. Reschke, C. Cyris, C. Cai, M. Jeffers, C. Peña, O. Bähr

Institutions: Heidelberg University, University of Tübingen, Rigshospitalet, Sarcoma Oncology Center, The University of Texas MD Anderson Cancer Center, University of Virginia, Ludwig-Maximilians-Universität München, National Cancer Center Hospital, Nagoya University Hospital, USC Norris Comprehensive Cancer Center, National Cancer Center Hospital East, Bayer (Germany), Bayer (United States), Goethe University Frankfurt, University Hospital Frankfurt

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2979189431

FWCI: 0.136

Cites:

Cited by: 5

Related to: 10